BioProcess International Europe is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Max Soegaard
Director, Process Development at ExpreS2ion Biotechnologies


Max Søgaard joined Expres2ion Biotechnologies in 2013 to set up a protein purification and characterisation department.  Working closely with clients he has since helped to convert non-cGMP, lab-scale protocols into fully scalable, reproducible, cGMP compliant processes in a number of projects currently in clinical phase I/II trials.  Max and a small team of scientists and technicians are working to expand the up- and downstream and analytical capabilities within Expres2ion Biotechnologies to meet the individual and diverse challenges of proteins for vaccine-antigens, diagnostics and therapeutics.  Max has a background in the field of structural protein biochemistry at University of Oxford as well as mechanisms of basal transcription (Ph.D., Clare Hall, Cancer Research UK) and translation termination (Cand.Scient, University of Aarhus, Denmark).

Max Soegaard's Network

Agenda Sessions

  • Development of new S2 cell lines for vaccine production